Amedisys (AMED) to Release Earnings on Wednesday

Amedisys (NASDAQ:AMEDGet Rating) will be issuing its quarterly earnings data after the market closes on Wednesday, April 27th. Analysts expect the company to announce earnings of $1.11 per share for the quarter. Amedisys has set its FY 2022 guidance at $5.230-$5.450 EPS and its FY22 guidance at $5.23-5.45 EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Amedisys (NASDAQ:AMEDGet Rating) last issued its quarterly earnings data on Wednesday, February 23rd. The health services provider reported $1.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.17 by $0.01. The firm had revenue of $559.32 million during the quarter, compared to the consensus estimate of $555.18 million. Amedisys had a net margin of 9.44% and a return on equity of 21.84%. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same period last year, the business posted $1.49 earnings per share. On average, analysts expect Amedisys to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Shares of AMED stock opened at $150.41 on Wednesday. The stock’s 50 day moving average is $157.06. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.95 and a quick ratio of 0.95. The firm has a market capitalization of $4.89 billion, a P/E ratio of 23.72, a PEG ratio of 2.63 and a beta of 0.72. Amedisys has a 12-month low of $122.12 and a 12-month high of $292.97.

AMED has been the subject of several research reports. initiated coverage on shares of Amedisys in a research report on Thursday, March 31st. They set a “hold” rating for the company. Barclays decreased their price objective on shares of Amedisys from $236.00 to $213.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 21st. Jefferies Financial Group reissued a “buy” rating and issued a $200.00 price objective on shares of Amedisys in a research note on Thursday, April 7th. Zacks Investment Research raised shares of Amedisys from a “sell” rating to a “hold” rating and set a $180.00 price objective on the stock in a research note on Tuesday, April 5th. Finally, SVB Leerink lifted their price objective on shares of Amedisys from $145.00 to $147.00 and gave the company a “market perform” rating in a research note on Friday, February 18th. Seven research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from, the stock has a consensus rating of “Buy” and a consensus target price of $193.56.

In other Amedisys news, insider David L. Kemmerly sold 2,500 shares of the business’s stock in a transaction on Tuesday, March 29th. The shares were sold at an average price of $177.31, for a total transaction of $443,275.00. Following the sale, the insider now owns 16,336 shares of the company’s stock, valued at $2,896,536.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.80% of the company’s stock.

Several large investors have recently modified their holdings of AMED. Morgan Stanley lifted its holdings in shares of Amedisys by 341.5% during the second quarter. Morgan Stanley now owns 132,183 shares of the health services provider’s stock worth $32,374,000 after purchasing an additional 102,246 shares during the period. Cetera Investment Advisers acquired a new position in Amedisys in the fourth quarter valued at $202,000. MML Investors Services LLC lifted its holdings in Amedisys by 58.0% in the fourth quarter. MML Investors Services LLC now owns 4,614 shares of the health services provider’s stock valued at $747,000 after buying an additional 1,693 shares during the period. Stifel Financial Corp lifted its holdings in Amedisys by 45.2% in the fourth quarter. Stifel Financial Corp now owns 40,835 shares of the health services provider’s stock valued at $6,610,000 after buying an additional 12,712 shares during the period. Finally, Sei Investments Co. lifted its holdings in Amedisys by 50.5% in the fourth quarter. Sei Investments Co. now owns 41,420 shares of the health services provider’s stock valued at $6,611,000 after buying an additional 13,892 shares during the period. Institutional investors own 92.18% of the company’s stock.

About Amedisys (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Recommended Stories

Earnings History for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with's FREE daily email newsletter.